[Pharmacological studies of a new analgesic agent, 2-phenyl-4-dimethylaminopropylamino-6-ethoxy-3(2H)pyridazinone hydrochloride (TM-3)].
D000632:Aminopyrine / Q000494:pharmacology / Q000633:toxicity; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000927:Anticonvulsants / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003864:Depression, Chemical; D004562:Electrocardiography; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D007422:Intestines / Q000187:drug effects; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D011724:Pyridazines / Q000494:pharmacology*; D051381:Rats; D012119:Respiration / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D013268:Stimulation, Chemical; D013270:Stomach / Q000187:drug effects; D014527:Uric Acid / Q000652:urine
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D011724:Pyridazines; D000632:Aminopyrine; D014527:Uric Acid